Serum Levels of 5-S-Cysteinyldopa Are Correlated with Skin Colors in Hemodialysis Patients but Not in Peritoneal Dialysis Patients

Murakami, Kazutaka; Nakanishi, Yusuke; Wakamatsu, Kazumasa; Yamamoto, Koichiro; Kohriyama, Nahoko; Hasegawa, Midori; Tomita, Makoto; Nabeshima, Kunihiro; Hiki, Yoshiyuki; Asano, Shinsuke; Kawashima, Shiro; Ito, Yasuhiro; Fujita, Yoshiro; Asada, Hiroaki; Nakai, Shigeru; Sugiyama, Satoshi; Itô, Shôsuke

doi:10.1159/000230812

Cited by 2 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some HD patients were found to have elevated levels of PB-DOPA [114]. The relation between skin colors and serum 5SCD levels in control subjects and in HD patients were summarized [117]. Serum 5SCD levels in HD patients were found to significantly correlate with skin color as measured by the melanin index (MI) and the erythema index (EI) values on the upper inner arm and by EI value on the forehead.…”

Section: Other Applications Influencing the 5scd Levelsmentioning

confidence: 99%

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Wakamatsu

Fukushima

Minagawa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.

show abstract

Section: Other Applications Influencing the 5scd Levelsmentioning

confidence: 99%

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Wakamatsu

Fukushima

Minagawa

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand CD levels in melanocytes, epidermis and blood seem not to depend on skin type (12,13). An increase of CD excretion in body fluids is associated with exposure to UV‐B (14) or UV‐A (15) light radiation or phototherapy (16) as well as with pathological states, primarily melanoma, making this metabolite a valuable disease progression marker (17), but has more recently been observed in diseases not involving melanocytes, like severe renal failure with hemodialysis treatments, where the diffuse hyperpigmentation was shown to be due to accumulation of pheomelanin in the skin (18,19).…”

Section: Introductionmentioning

confidence: 99%

Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis

Panzella¹,

Wakamatsu²,

Monfrecola³

et al. 2011

Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

The possible role of melanocyte as a modulator of the inflammation and keratinocyte hyperproliferation in psoriasis has been hypothesised but never demonstrated on experimental basis. Aim of the present study was to assess whether plasma levels of 5-S-cysteinyldopa (CD), a metabolite reflecting melanocyte activity, undergo changes in association with psoriasis together with those of typical lipid peroxidation markers thiobarbituric acid reactive substances (TBARS). A group of 16 patients with psoriasis at different stage as indicated by the psoriasis area and severity index (PASI) were enrolled against an age and sex matched control group. Both TBARS (P < 0.05) and CD (P < 0.005) levels were higher than controls with statistical significance. After 1 month therapy the levels of either biomarkers decreased with respect to the starting values although with marked individual differences. CD may represent a novel and sensitive biomarker for the follow up of psoriasis and evaluation of the efficacy of therapeutic regimens beyond PASI determination.

show abstract

Serum Levels of 5-S-Cysteinyldopa Are Correlated with Skin Colors in Hemodialysis Patients but Not in Peritoneal Dialysis Patients

Cited by 2 publications

References 45 publications

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis

Contact Info

Product

Resources

About